Table 1 Baseline demographic and clinical profiles in HFEM and CM patients

Age (years. Mean. SD)

44.2 (11.7)

47.9 (16.7)

.127

Sex (%. Females)

82.4

80.6

1.000

BMI (kg/m². median. IQr)

23.20 (4.25)

23.00 (3.68)

.487

 Psychiatric

18.8

20.5

1.000

 Gastrointestinal

7.1

14.8

.367

 Vascular

0

6.1

.345

 Hormonal

14.3

10.5

.521

 Cancer

10.7

1.8

.053

 Respiratory

3.6

1.8

.485

 Diabetes

0

2.7

1.000

 Hypertension

7.1

15.8

.365

 Immuno- rheumatologic

3.6

4.4

1.000

 Overweight

36.4

28.6

.468

 Other

17.9

12.1

.531

MO (%)

20.6

85.3

<.001

Disease history (years. Median. IQr)

26 (22)

30 (13)

.117

Pain characteristics (%)

.033

 throbbing

46.9

70.7

 dull

50.0

28.5

 other

3.1

0.8

Dopaminergic features (%)

57.1

64.0

.519

Allodynia (%)

43.8

67.5

.023

Unilateral cranial autonomic features (%)

46.4

48.2

.863

Temporal artery hyperpulsatility (%)

11.5

23.1

.274

Number of failed preventives (median. IQr. [min-max])

4 (3) [3–12]

5 (3) [3–12]

.008

Triptan efficacy degree (median. IQr)

2 (1)

1 (1)

<.001

NRS (median. IQr)

7 (1)

8 (1)

.038

MMDs (median. IQr)

11 (3)

20 (10)

<.001

MHDs (median. IQr)

11 (4)

21 (12)

<.001

MPI (median. IQr)

12 (5)

20 (15)

<.001

HIT-6 (median. IQr)

66 (8)

68 (8)

.114

MIDAS (median. IQr)

30 (29)

72 (60)

<.001